SACCHI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.997
EU - Europa 13.252
AS - Asia 9.490
SA - Sud America 1.264
AF - Africa 225
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 17
Totale 47.283
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.766
GB - Regno Unito 6.331
CN - Cina 3.557
SG - Singapore 2.575
IT - Italia 1.735
HK - Hong Kong 1.482
SE - Svezia 1.318
BR - Brasile 1.053
DE - Germania 1.001
UA - Ucraina 744
RU - Federazione Russa 547
TR - Turchia 487
FI - Finlandia 431
VN - Vietnam 416
FR - Francia 325
KR - Corea 278
BG - Bulgaria 257
IN - India 141
CA - Canada 124
MA - Marocco 124
ID - Indonesia 112
IE - Irlanda 104
AR - Argentina 87
JP - Giappone 81
NL - Olanda 81
PL - Polonia 73
BD - Bangladesh 56
MX - Messico 54
ES - Italia 42
MY - Malesia 41
BE - Belgio 39
CH - Svizzera 39
ZA - Sudafrica 39
EC - Ecuador 36
CZ - Repubblica Ceca 33
IQ - Iraq 33
AU - Australia 30
LT - Lituania 30
IR - Iran 29
AT - Austria 28
CO - Colombia 27
PK - Pakistan 23
RO - Romania 22
TW - Taiwan 22
AE - Emirati Arabi Uniti 19
IL - Israele 18
SA - Arabia Saudita 18
CL - Cile 16
UZ - Uzbekistan 16
KE - Kenya 14
AZ - Azerbaigian 13
BZ - Belize 13
PE - Perù 13
EU - Europa 12
PH - Filippine 11
PT - Portogallo 11
PY - Paraguay 11
VE - Venezuela 11
EG - Egitto 10
TN - Tunisia 10
AL - Albania 9
JM - Giamaica 9
JO - Giordania 9
HU - Ungheria 8
KZ - Kazakistan 8
NO - Norvegia 8
NZ - Nuova Zelanda 8
HR - Croazia 7
PA - Panama 7
KG - Kirghizistan 6
DK - Danimarca 5
DO - Repubblica Dominicana 5
GR - Grecia 5
NP - Nepal 5
TH - Thailandia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BH - Bahrain 4
BO - Bolivia 4
CR - Costa Rica 4
DZ - Algeria 4
ET - Etiopia 4
LB - Libano 4
LY - Libia 4
SN - Senegal 4
UY - Uruguay 4
BN - Brunei Darussalam 3
GP - Guadalupe 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
CY - Cipro 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
MD - Moldavia 2
MK - Macedonia 2
PS - Palestinian Territory 2
SI - Slovenia 2
Totale 47.247
Salva come PNG Salva come JPEG
Città #
Southend 5.360
Santa Clara 2.176
Fairfield 2.102
Ashburn 1.722
Singapore 1.562
Woodbridge 1.524
Jacksonville 1.495
Hong Kong 1.475
Chandler 1.443
Hefei 1.212
Houston 1.204
Dearborn 1.033
Ann Arbor 1.031
Wilmington 808
Nyköping 756
Seattle 723
Cambridge 691
Beijing 675
London 596
Los Angeles 380
Modena 314
Chicago 300
Princeton 289
Seoul 267
Eugene 261
San Diego 256
Sofia 255
New York 251
Izmir 250
The Dalles 208
Des Moines 193
Moscow 164
Frankfurt am Main 160
Buffalo 157
Ho Chi Minh City 152
Helsinki 143
Milan 135
Munich 121
Salt Lake City 119
Council Bluffs 118
Shanghai 115
Casablanca 105
Dublin 99
Rome 96
Columbus 89
Falls Church 86
Hanoi 85
São Paulo 81
Redwood City 78
Jakarta 73
Boardman 62
Dallas 62
Bremen 60
Elk Grove Village 57
Norwalk 56
Guangzhou 52
Warsaw 49
Fremont 48
Nanjing 48
Turku 47
Phoenix 43
Tokyo 42
Tampa 39
Brussels 38
Kunming 36
Montreal 35
Sterling 35
Toronto 34
Rio de Janeiro 32
San Jose 32
Jinan 31
Turin 30
Belo Horizonte 29
Brooklyn 28
Dong Ket 28
Lancaster 28
Naples 28
San Mateo 27
Denver 26
Tivoli 26
Kent 25
Verona 25
Atlanta 24
Brno 23
Changsha 23
Poplar 23
Bologna 22
Boston 22
Saint Petersburg 22
Nuremberg 21
San Francisco 21
Stockholm 21
Wuhan 21
Brasília 20
San Giuliano Milanese 20
Johannesburg 19
Nanchang 19
Palermo 19
Indiana 18
Ottawa 18
Totale 34.602
Salva come PNG Salva come JPEG
Nome #
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 624
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 581
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 449
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 440
Utilità clinica del dosaggio della beta-tromboglobulina e del fattore piastrinico 4 405
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 398
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 380
Cinetica piastrinica e indicazione alla splenectomia nella porpora trombocitopenica idiopatica 366
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 361
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 353
Cell-penetrating CaCO3nanocrystals for improved transport of NVP-BEZ235 across membrane barrier in T-cell lymphoma 350
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 345
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 341
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 332
Activity of BKM120 and BEZ235 against lymphoma cells 326
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 324
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 319
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines 313
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 313
Leucemia eosinofila cronica: descrizione di un caso clinico a lunga sopravvivenza 312
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 310
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 299
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 298
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 298
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 295
A concise review of lenalidomide therapy for follicular lymphoma 290
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 288
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 284
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 280
Diagnosis of essential thrombocythemia at platele counts between 400 and 600x10(9)/L. 274
Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience 274
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 271
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 265
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 262
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 262
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 261
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 259
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 255
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 255
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 255
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 254
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 252
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 250
Alpha-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Group on ET 248
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 246
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases 246
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 243
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 241
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 240
Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia 239
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 239
Epidermiological, diagnostic, therapeutic and prognostic aspects of essential thrombocithemia in a retrospective study of the GIMMC group in two thousand patients. 238
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 238
Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. 237
A PROSPECTIVE COMPARISON BETWEEN TREATMENT WITH PHLEBOTOMY ALONE AND WITH INTERFERON-ALPHA IN PATIENTS WITH POLYCYTHEMIA-VERA 236
Chromosomes in paroxysmal nocturnal haemoglobinuria. 236
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 236
Isodicentric X chromosome in myeloproliferative disorders. 233
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 233
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 232
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 231
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 231
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 230
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 229
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 227
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 225
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 225
Acute nonlymphocytic leukemia with trisomy 4. 220
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 219
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 218
THE USE OF THE ALKALINE PHOSPHATASE-ANTIALKALINE PHOSPHATASE TECHNIQUE FOR IMMUNOPHENOTYPING ACUTE MYELOID-LEUKEMIA 218
Extremely low frequency pulsed electromagnetic fields increase cell proliferation in lymphocytes from young and aged subjects. 215
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 214
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 213
Effects of Enzastaurin, Alone or in Combination, on Signalling Pathway Controlling Growth and Survival of B-Cell Lymphoma Cell LinesBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 4978 213
Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab (FC+R) in Relapsed Follicular Lymphoma Patients. 212
Cromosomi marker ed anomalie nucleari nei linfociti di due pazienti con sindrome di Sezary/micosi fungoide. In problemi e prospettive nella medicina moderna. 212
Analysis of proliferation activity of myeloid leukaemia cell subsets in ANLL 210
The Oral PKC-ß Inhibitor Enzastaurin (LY317615) Suppress Phosphorylation and Induces Apoptosis in Multiple Myeloma Cell Lines by Inhibition of AKT Pathway. 210
Alterazione della regione p22-p23 del cromosoma 6 associata a sindrome mieloproliferativa (MPS). 209
Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes. 209
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 208
Low-dose intravenous pepsin-treated gammaglobulin for idiopathic thrombocytopenic purpura in adults. 207
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors 207
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 207
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 205
Leucemia e tricoleucociti: studio clinico patologico di 30 casi 205
Non-Hodgkin Lymphoma in Psoriatic Arthritis Treated with Sequential, Multiple Anti-TNF-α Agents: A Case Report 205
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. 205
All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi) 204
Sinus histiocytosis with massive lymphadenopathy. 204
Descrizione di un metodo semplificato per lo studio della cinetica piastrinica 204
Evaluation of platelet kinetics and some coagulation parameters in diabetic retinopathy. 202
Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression 202
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 201
Systemic sarcoidosis associated with interferon-alpha treatment for chronic myelogenous leukemia 200
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 199
Su di un caso di plasmocitoma solitario extramidollare 198
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 195
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study 195
Totale 26.427
Salva come PNG Salva come JPEG
Categoria #
all - tutte 171.879
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 171.879
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.662 0 0 0 0 0 310 372 544 231 550 421 234
2021/20224.305 114 538 357 443 160 285 188 264 481 280 582 613
2022/20234.224 523 480 272 401 462 745 92 390 510 41 198 110
2023/20242.701 123 154 168 209 617 214 461 275 57 47 108 268
2024/20258.470 328 86 112 616 1.717 1.195 626 412 1.010 429 785 1.154
2025/20267.774 1.064 785 1.423 1.856 2.245 401 0 0 0 0 0 0
Totale 47.564